Inhibrx Biosciences, Inc.

INBXReported to SECin USCIK 0002007919Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 23. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 23
Form 4 lines at Inhibrx Biosciences, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Lappe MarkChief Executive OfficerOpen-market buy$305,1063,000 sharesSep 28, 2026Lappe MarkChief Executive Officer$305,106Buy · Sep 28Open-market buy3,000Sep 28, 2026
Lappe MarkChief Executive OfficerOpen-market buy$148,3201,500 sharesSep 28, 2026Lappe MarkChief Executive Officer$148,320Buy · Sep 28Open-market buy1,500Sep 28, 2026
Lappe MarkChief Executive OfficerOpen-market buy$216,7272,176 sharesSep 28, 2026Lappe MarkChief Executive Officer$216,727Buy · Sep 28Open-market buy2,176Sep 28, 2026
Lappe MarkChief Executive OfficerOpen-market buy$328,6303,324 sharesSep 28, 2026Lappe MarkChief Executive Officer$328,630Buy · Sep 28Open-market buy3,324Sep 28, 2026
Kayyem Jon Faiz—Open-market buy$500,0005,000 sharesSep 23, 2026Kayyem Jon Faiz$500,000Buy · Sep 23Open-market buy5,000Sep 23, 2026